Evaluating AI-Assisted Health Education to Improve Clinical Trial Awareness and Participation in Adults with Blood Cancers

What this Trial Is About

Researchers are evaluating the use of artificial intelligence AI technology to improve health education among patients with haematological cancers such as leukaemia, lymphoma, multiple myeloma, and related disorders. The study aims to assess how AI-assisted education affects patients understanding of clinical trials and their intention to participate in them. This research seeks to explore the benefits of AI-powered chatbots in delivering personalized health information and supporting patient decision-making for clinical trial participation. Participants are divided into two groups. One group receives standard health education plus clinical trial-specific education delivered through an AI robot featuring voice interaction and multimedia displays to enhance understanding. The other group receives only routine health education from healthcare staff covering disease knowledge and treatment but without dedicated clinical trial information. This is a randomized controlled trial designed to compare these two approaches. During the study, participants will be assessed on their intention to participate in clinical trials at the start of enrollment and one week after completing the intervention. Researchers will also evaluate user experience seven days post-intervention. The study involves collecting data on patients cognitive levels, attitudes, and participation intentions to understand the impact of AI-assisted education. The total participation period includes a one-week intervention and post-intervention assessments.

Randomised Controlled Trial of Artificial Intelligence-assisted Health Education